Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (Pegloticase) (MIRROR)

Trial Profile

A Phase 2, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (Pegloticase) (MIRROR)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs Methotrexate (Primary) ; Pegloticase (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms MIRROR
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 07 Nov 2018 According to a Horizon Pharma media release, the company is currently adapting this clinical trial design to support the potential for registration and expects to begin enrolling patients into the adapted protocol in the second quarter of 2019.
    • 27 Sep 2018 According to Horizon Pharma media release, first patient has been enrolled in this trial.
    • 20 Sep 2018 Planned End Date changed from 14 Oct 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top